What is Synlogic?
Synlogic is a biotechnology innovator at the forefront of synthetic biology, dedicated to transforming the treatment of complex diseases. The company utilizes a modular, reproducible approach to microbial engineering, designing Synthetic Biotic medicines that target underlying biological mechanisms. Its pipeline addresses significant unmet needs in metabolic disorders, such as phenylketonuria and homocystinuria, while simultaneously expanding its reach into immunology. By leveraging a horizontal platform for cell programming, Synlogic occupies a unique market position that bridges the gap between computational design and therapeutic application.
How much funding has Synlogic raised?
Synlogic has raised a total of $283.9M across 6 funding rounds:
Series A
$34.4M
Series B
$40M
Series C
$42M
Stock Offering
$57.5M
Stock Offering
$30M
Corporate Investment
$80M
Series A (2014): $34.4M with participation from Bill & Melinda Gates Foundation, Atlas Ventures, and NEA
Series B (2016): $40M led by Deerfield Management Company, NEA, OrbiMed, and Atlas Ventures
Series C (2017): $42M supported by CLI Ventures, Ally Bridge Group, Arctic Aurora LifeScience, Rock Springs Capital, Aju IB Investment, NEA, Deerfield, Perceptive Advisors, OrbiMed, and Atlas Ventures
Stock Issuance/Offering (2018): $57.5M featuring Undisclosed
Stock Issuance/Offering (2018): $30M backed by Undisclosed
Corporate Investment (2019): $80M with participation from Ginkgo Bioworks
Key Investors in Synlogic
Atlas Ventures
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
NEA
New Enterprise Associates is a global venture capital firm that invests in technology and healthcare companies at all stages, from seed to IPO.
What's next for Synlogic?
With significant capital reserves secured, Synlogic is well-positioned to accelerate its clinical pipeline and deepen its strategic partnerships. The company's focus remains on the validation of its Synthetic Biotic platform, with future growth likely driven by the expansion of its immunology portfolio and the optimization of its cell programming capabilities. As the firm moves forward, it will likely prioritize the commercialization of its lead assets while maintaining its collaborative model with industry leaders to enhance its therapeutic reach and operational efficiency.
See full Synlogic company page
